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Abstract
Background: Experimental examinations of biofluids to measure concentrations of proteins or
their fragments or metabolites are being explored as a means of early disease detection,
distinguishing diseases with similar symptoms, and drug treatment efficacy. Many studies have
produced classifiers with a high sensitivity and specificity, and it has been argued that accurate
results necessarily imply some underlying biology-based features in the classifier. The simplest test
of this conjecture is to examine datasets designed to contain no information with classifiers used
in many published studies.
Results: The classification accuracy of two fingerprint-based classifiers, a decision tree (DT)
algorithm and a medoid classification algorithm (MCA), are examined. These methods are used to
examine 30 artificial datasets that contain random concentration levels for 300 biomolecules. Each
dataset contains between 30 and 300 Cases and Controls, and since the 300 observed
concentrations are randomly generated, these datasets are constructed to contain no biological
information. A modest search of decision trees containing at most seven decision nodes finds a
large number of unique decision trees with an average sensitivity and specificity above 85% for
datasets containing 60 Cases and 60 Controls or less, and for datasets with 90 Cases and 90
Controls many DTs have an average sensitivity and specificity above 80%. For even the largest
dataset (300 Cases and 300 Controls) the MCA procedure finds several unique classifiers that have
an average sensitivity and specificity above 88% using only six or seven features.
Conclusion:  While it has been argued that accurate classification results must imply some
biological basis for the separation of Cases from Controls, our results show that this is not
necessarily true. The DT and MCA classifiers are sufficiently flexible and can produce good results
from datasets that are specifically constructed to contain no information. This means that a chance
fitting to the data is possible. All datasets used in this investigation are available on the web.
This work is funded by NCI Contract N01-CO-12400.
Background
It is well established that early detection of cancer often
results in a better prognosis. This detection has relied on
measuring the concentration of a particular protein or
biomarker, such as cancer antigen (CA)-125 for ovarian
cancer and prostate specific antigen (PSA) for prostate
cancer. Unfortunately, many of the commonly used
biomarkers have a low sensitivity and/or specificity which
Published: 17 December 2008
BMC Bioinformatics 2008, 9:545 doi:10.1186/1471-2105-9-545
Received: 23 April 2008
Accepted: 17 December 2008
This article is available from: http://www.biomedcentral.com/1471-2105/9/545
© 2008 Luke and Collins; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Bioinformatics 2008, 9:545 http://www.biomedcentral.com/1471-2105/9/545
Page 2 of 9
(page number not for citation purposes)
necessitate the search for new biomarkers. Clinically it is
useful if the measurement of a biomarker be obtained
from a readily available biofluid, such as blood, urine,
tears, or mucous. Bioinformatic analysis of data obtained
from biofluids may result in identifying new biomarkers.
The standard procedure is to obtain biofluid samples
from individuals with known histologies and perform an
search of experimentally measured quantities, or features,
to construct and test a classifier. This is done by dividing
those individuals with and without a given disease into a
training set and a testing set. The training set is used to
construct a classifier from a subset of the features such that
it accurately determines whether an individual has the dis-
ease. If such a classifier can be found, the testing samples
are then examined to verify its accuracy. The goal of this
procedure is to construct a classifier that can effectively be
used on the underlying population; which Ransohoff
denoted as generalizability [1,2].
While multiple biomarkers can classify a given individual
better than a single biomarker [3], and it has been argued
that tens to hundreds of biomarkers may be required [4],
it is important to examine the way in which these markers
are used in a classifier. While many forms of a classifier are
possible, any classifier can be considered to lie between
two possible extremes. At one extreme are classifiers
denoted fingerprint-based classifiers, and at the other are
classifiers denoted biomarker-based classifiers.
As the name implies, a fingerprint-based classifier is simi-
lar to the forensic procedure that determines whether or
not a given individual was at a particular location. It uses
a subset of the available features, or panel of markers, to
construct a pattern and this overall pattern, or proteomic
fingerprint, is used to identify the closest matching indi-
vidual. In disease classification, if the match to an individ-
ual with a known histology (diseased or healthy) is
sufficiently close, then the tested sample belongs to an
individual with the same histology.
An example of a fingerprint-based classifier is the medoid
classification algorithm (MCA) used in many studies from
the laboratories of Emmanuel Petricoin and Lance Liotta
[5-10]. This procedure scales the set of N selected feature
values such that each training sample represents a point in
an N-dimensional unit hypercube. A test sample is then
scaled and placed in this hypercube, and if it is sufficiently
close to one of the training samples it is given the same
histology as this training sample. Every sample in the test-
ing set must have a sufficiently similar sample in the train-
ing set, or else a prediction cannot be made.
The other extreme for classifiers is represented by a stand-
ard biomarker-based classifier. Here filtering methods are
used to determine if the values of an isolated feature suf-
ficiently distinguishes between diseased and healthy indi-
viduals. If a small number of such features are found, and
their predictive ability is not caused by a bias in the study
design, these features represent putative biomarkers and
the classifier only uses these features. In a study of individ-
uals with and without colorectal cancer it was found that
the blood concentration of the complement C3a-desArg is
elevated in individuals with either colorectal polyps or
colorectal cancer [11,12]. Other studies have shown that
complement C3a-desArg is also elevated in individuals
with benign prostate hyperplasia [13,14] and Type-2 dia-
betes [15]. Therefore, a sufficiently low concentration of
complement C3a-desArg in the blood may be sufficient to
exclude any of these conditions; extra tests would have to
be performed on an individual with a high blood concen-
tration to correctly identify the condition.
A decision tree (DT) classifier [16-28] can be considered
to be between these extremes. If a sufficiently accurate DT
classifier only requires a single decision node, then the
feature used by this node represents a putative biomarker
and this is a biomarker-based classifier. Since only the ini-
tial, or root node acts on all samples in the training set,
any additional nodes only examine a subset of the train-
ing samples, and the members of this subset depends on
the features used in any preceding nodes. The decision
tree shown in Figure 1 contains seven decision nodes
(labeled 1 through 7) that produce eight terminal nodes
(labeled 8 through 15). If a feature used in decision node
2 is changed to another feature, for example, then the
samples that are passed to nodes 4 and 5 would be
changed. This would affect the quality of the discrimina-
tors for these latter nodes and the quality of the classifier.
In other words, the optimal features to use in nodes 4 and
5 depend upon which features are used in nodes 1 and 2,
while the optimal features in nodes 6 and 7 depend upon
what features are used in nodes 1 and 3.
The main point is that a fingerprint-based classifier
depends on the pattern of feature values across all N fea-
tures used in the classifier. Changing one of the features
used in an MCA classifier would necessarily change the
location of all training samples in the N-dimensional unit
hypercube and may drastically alter the classification
accuracy for the testing samples. A multi-node DT has
some of this property in that changing the features used in
Nodes 1 through 3 in Figure 1 will change some or all of
the sample subsets passed to decision nodes 4 through 7,
and therefore change the classification accuracy and the
optimal features to use in these latter nodes.
It is understood that if bias can be removed from consid-
eration, a single feature that correctly distinguishes
healthy from diseased individuals represents a putativeBMC Bioinformatics 2008, 9:545 http://www.biomedcentral.com/1471-2105/9/545
Page 3 of 9
(page number not for citation purposes)
biomarker that may be directly involved with the disease
progression or with the host's response to this disease.
Gillette and coworkers [29] have argued that the pro-
teomic pattern or fingerprint associated with a panel of
markers can be thought of as a single biomarker. There-
fore, it has been stated [30] that if a fingerprint-based clas-
sifier is able to sufficiently predict the histology of
individuals in an independent testing set, then this classi-
fier must reflect some underlying biological principles.
This assumption of accurate predictions being a necessary
and sufficient condition for biological significance is
tested in this manuscript. If any given classifier is able to
accurately classify both a training set and a testing set
using a panel of markers from a dataset that contains no
biological information, then this association between
good results being a necessary and sufficient condition for
an underlying biological principle is disproved.
A random number generator is used to construct 30 data-
sets that contain no biological information. As described
in the Methods section, each dataset contains the same
number of Cases and Controls and each sample contains
random values for 300 features. Current microarray and
mass spectroscopic studies generate far more than 300 fea-
tures, so this study investigates the flexibility of a classifi-
cation algorithm instead of exploring the "curse of
dimensionality." The number of Cases and Controls were
set to 30, 42, 60, 90, 150, and 300; and five random data-
sets were constructed for each number of Cases and Con-
trols. Therefore the smallest five datasets contained
random feature intensities for 30 Cases and 30 Controls,
and they represent situations where a chance fitting [1,2]
of the data may be possible. The largest five datasets con-
tain 300 features and 600 samples (300 Cases and 300
Controls) and a chance fitting of the data is not expected.
All 30 datasets are available on the web [31] and any algo-
rithm that produces good classification results can only
do so by chance. Any acceptable classification disproves
the sufficiency condition between accurate classification
results and biological information. In other words, this
"proof by counter example" argues against the contention
that an accurate classification is sufficient to assume a bio-
logical relevance, and may underline the disconnect
between many accurate classification studies and the lack
of biomarkers that have been approved by the FDA.
In this study, the DT and MCA methods are used to exam-
ine these 30 different datasets. The DT procedure uses the
symmetric decision tree shown in Figure 1 with seven
decision nodes and eight terminal nodes, though for
some runs pruning is performed for a putative classifier
prior to determining its classification accuracy. The MCA
method is used to construct classifiers containing five, six,
or seven features from the set of 300. A complete analysis
of these datasets would require an exhaustive testing of all
possible sets of seven features in all possible orders for the
DT method and all possible sets of five, six and seven fea-
tures for the MCA method. Since this is not computation-
ally feasible, a modified Evolutionary Programming (EP)
algorithm [32] is used to search for near-optimal sets of
features. This procedure selects sets of features that are
passed to the DT and MCA algorithms to construct puta-
tive classifiers. This EP algorithm uses the classification
accuracy of the putative classifiers to construct a final pop-
ulation of classifiers that accurately predict the histology
of the samples.
Since the EP procedure is a stochastic search algorithm
that samples a small subset of the available sets of fea-
tures, finding the best set of features in a given run is not
guaranteed. Therefore, for each classification method and
dataset, multiple runs are performed. The DT procedure is
run four times for each dataset, each with a different seed
to the random number generator. In two of the runs no
pruning is performed and in the other two a decision
node is converted to a terminal node of it contains less
than 4% of either the Cases or Controls. Each dataset is
also examined twice by the MCA method for each number
of features (five, six or seven). These two runs not only use
different seeds to the random number generator but use a
different ordering of the samples since (as described in the
Methods section) the final result depends upon this order-
ing. Since finding the best set of features is not guaranteed,
the results presented here should be taken as a lower
bound, or minimum estimate, of the sensitivity and spe-
cificity that would be obtained for each procedure if an
exhaustive search were performed.
Node numbering for the decision trees Figure 1
Node numbering for the decision trees. This investiga-
tion uses a decision tree containing seven decision nodes 
(Nodes 1 through 7) and eight terminal nodes (Nodes 8 
through 15).BMC Bioinformatics 2008, 9:545 http://www.biomedcentral.com/1471-2105/9/545
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Results and discussion
A summary of the classification results for these artificial
datasets is shown in Table 1. The first column lists the
number of Cases and Controls and the rows correspond
to the best results obtained from the five corresponding
datasets. The first section of results in Table 1 lists the
highest quality (sensitivity plus specificity as percentages)
for the DT algorithm. Since each dataset was examined
four times, the qualities represent the best results over 20
runs (four runs using five different datasets). The DT clas-
sification accuracy for the best and 200th best classifier for
each of the four runs using each dataset is listed in Addi-
tional file 1. The second section of results in Table 1 lists
the highest quality (sensitivity plus specificity) for the
MCA classifier using five, six or seven features. Since each
dataset was examined twice for a given number of fea-
tures, these results represent the highest quality obtained
over 10 runs (two examinations of five datasets). The
MCA qualities for the best and 200th best classifier in each
of the six runs for each dataset are listed in Additional file
2.
It should be noted that, for the MCA algorithm, each time
the Cases were examined before the Controls all 200 clas-
sifiers produced a sensitivity of 100%, while each time the
Controls were examined before the Cases the specificity
was always 100%, independent of the number of Cases
and Controls. This is a design feature of the MCA algo-
rithm. Each time a sample is examined it is either placed
in an existing cell or it becomes the medoid of a new cell.
If only Cases are initially examined, they have to be placed
in an existing Case-cell or create a new Case-cell. Either sit-
uation produces a correct classification of this Case sam-
ple. Though the exact sensitivity and specificity depend
upon the order of the samples examined, their sum is rel-
atively constant for the different ordering (see Additional
file 2).
The DT classifier shows that the accuracy of the best iden-
tified classifier decreases as the number of samples
increases. All of the 20 runs for the smallest datasets (30
Cases and 30 Controls) identified at least one decision
tree whose average sensitivity and specificity was 95% or
better and three of the 20 runs found at least one decision
tree that produced perfect results (sensitivity = specificity
= 100%). In fact one of these runs identified at least 200
unique decision trees that yield perfect results (see Addi-
tional file 1).
For the datasets with 60 Cases and 60 Controls, the runs
identified at least one decision tree whose average sensi-
tivity and specificity ranged from 85% to over 89%. The
overall results for the best decision tree and a hypothetical
division into a training set and a testing set is shown in
Table 2. The training set has a sensitivity and specificity of
95.0 and 85.0%, respectively, while the testing set has a
sensitivity of 90.0% and a specificity of 85.0%. It should
be stressed that this division is not the only one that places
40 Cases and 40 Controls in the training set and 20 Cases
and 20 Controls in the testing set while preserving the
character of the eight terminal nodes as Case-nodes or
Control-nodes: there are approximately 1.09 × 1027
unique ways that these 120 samples can be placed into
this specific division.
For the datasets with 90, 150, and 300 Cases and Con-
trols, at least one run identified a decision tree with an
average sensitivity and specificity above 83.3, 77.6, and
69.1%, respectively. The best results presented in Table 1
should be taken as lower bounds to the accuracy for a ran-
dom dataset containing no biological information due to
the small population size and number of generations in
the modified evolutionary programming (mEP) search
[32] and a modest search for the optimum cut points for
each decision tree.
Significantly better results are obtained when the MCA
method is used to fit the random datasets. If only five fea-
tures are used, which is the minimum number considered
in many previous publications [5-10], all 10 runs found at
least one classifier that produced perfect results (sensitiv-
ity = specificity = 100%) for the datasets with 30 Cases and
30 Controls (see Additional file 2). When six or seven fea-
tures are used, all 10 runs again found at least one perfect
classifier, with two of the six-feature runs and four of the
seven-feature runs producing final populations with at
least 200 perfect classifiers. When the number of Cases
and Controls is increased to 42, the best results yielded an
average sensitivity and specificity of 98.8%, independent
of the number of features. For 60 Cases and 60 Controls,
both the five-feature and six-feature runs found at least
one classifier with an average sensitivity and specificity of
over 96.6%, while the seven-feature runs found at least
one classifier with an average sensitivity and specificity of
97.5%.
Table 1: Highest quality obtained from the DT and MCA 
classifiers
Cases & Controls MCA
DT 5 Peaks 6 Peaks 7 Peaks
30 200.0 200.0 200.0 200.0
42 190.5 197.6 197.6 197.6
60 178.3 193.3 193.3 195.0
90 166.7 187.8 188.9 191.1
150 155.3 183.3 185.3 187.3
300 138.3 170.3 179.0 180.3
The reported quality is the largest sum of the sensitivity and 
specificity (in percent) found across the five random datasets for each 
number of Cases and Controls for a decision tree (DT) using at most 
seven decision nodes and the medoid classifier algorithm (MCA).BMC Bioinformatics 2008, 9:545 http://www.biomedcentral.com/1471-2105/9/545
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As described in Methods, the MCA classifier is constrained
so that at most two-thirds of the Cases and Controls are
used to establish Case and Control proteomic fingerprint
patterns, respectively. This means that at least one-third of
all Cases and Controls are not needed to establish these
fingerprints and can represent a testing set.
Table 3 lists the results for two different MCA classifiers
using the same dataset treated by the DT classifier in Table
2. The MCA results in Table 1 and Additional file 2 first
examined all Cases or Controls and then all samples in
the other group, but for the results in Table 3 the samples
were reordered so that there was a intermixing of the 60
Cases and 60 Controls. Both classifiers effectively used 40
Cases and Controls for the training set and 20 Cases and
Controls for the testing set. They have a sensitivity and
specificity of 97.5% for the training set and 95.0% for the
testing set. Though all samples used to define a medoid
must be part of the training set, there are still 1.51 × 109
unique ways that the remaining samples can be divided
between training and testing sets for the first classifier and
9.49 × 106 unique ways to divide the remaining samples
for the second classifier to obtain the division shown in
Table 3. These two results were obtained using different
seeds to the random number generator in the mEP search,
and additional classifiers could be determined using a dif-
ferent seed or a different ordering of the samples in the
dataset.
For the datasets with 90, 150, and 300 Cases and Con-
trols, the MCA results show a monotonic decrease in the
average sensitivity and specificity as the number of sam-
ples increases. For the largest dataset (300 Cases, 300 Con-
trols, and 300 features), at least one seven-feature
classifier produced an average sensitivity and specificity
above 90.1%.
It has been argued that good classification results for a test
set that in no way is used to determine the classifier nec-
essarily implies that the classifier is based on some under-
lying biological information [30]. The results presented
here show that good classification accuracy is not a suffi-
cient condition to imply a biological basis for studies that
use a DT or MCA classifier. If a good classification result
implies a sensitivity and specificity of at least 85%, a deci-
sion tree with at most seven decision nodes can obtain
this result from a random dataset containing more than
60 Cases and 60 Controls. If this threshold is increased to
90%, a decision tree can achieve this accuracy for a ran-
dom dataset containing fewer than 60 Cases and 60 Con-
trols, while a medoid classification algorithm achieves
this accuracy with a pattern of seven features for a dataset
containing 300 Cases and 300 Controls.
These results show that the quality of these classifiers will
not decrease if more features are used in the fingerprint.
Increasing the number of features into the hundreds [4]
assures that a dataset containing even greater numbers of
samples can be fit by chance [1,2] using a fingerprint-
based classifier. It is important to note that these results
are obtained for datasets containing only 300 features for
each sample. Current separation technologies which yield
multiple mass spectra for each sample as well as microar-
ray studies produce many times more features per sample
than considered here. Increasing the number of available
features for each sample will also increase the quality of
the classification using a DT or MCA, whether or not the
dataset contains any biological information.
In a response to criticism that different studies used differ-
ent features to accurately classify individuals with a given
disease [33], it was stated that "the generation of multiple
combinations of diagnostic features from the same start-
ing data is a logical consequence of the complexity of the
information content" [34]. The results in Tables 2 and 3
demonstrate that this statement is not absolutely true.
Three classifiers each used seven features to accurately
classify the same dataset that contains no biological infor-
mation and only feature 140 was used in both the DT and
an MCA classifier. The second MCA classifier used a set of
seven features that were completely different from the 13
used in the other two. This is not a result of the complexity
of the information content of the dataset, since it is
designed to contain no information, but is due to the flex-
ibility of the classifiers and their ability to generate a good
fit only using noise.
It should be stressed that this investigation only examines
the classification accuracy of fingerprint-based classifiers.
In a fingerprint-based classifier, different combinations of
Table 2: Hypothetical placement of 60 Cases and Controls in training and testing sets
Node 8 Node 9 Node 10 Node 11 Node 12 Node 13 Node 14 Node 15
Overall 0:6 15:0 0:17 2:0 35:9 2:8 2:20 4:0
Training 0:5 10:0 0:11 2:0 23:6 1:5 1:13 3:0
Testing 0:1 5:0 0:6 0:0 12:3 1:3 1:7 1:0
Overall placement of 60 Cases and 60 Controls (Cases:Controls) in the eight terminal nodes of the best decision tree shown in Table 1 and a 
hypothetical distribution between a training set and a testing set. Features 198, 140, 99, 68, 41, 95, and 251 are used in decision nodes 1 through 7 
(Figure 1), respectively.BMC Bioinformatics 2008, 9:545 http://www.biomedcentral.com/1471-2105/9/545
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features are examined and the "panel of markers" that
produces the best result can be considered a single
biomarker [29]. There is no point in examining each fea-
ture in this panel, since it is their concerted action that
produces the classifier, and identifying the specific protein
responsible for each of these peaks [35] would not be suf-
ficient to claim that they represent biomarkers. Pre-screen-
ing potential features for their discriminating ability
before using them in the final classifier [36] is representa-
tive of a biomarker-based classifier and is outside the
scope of this investigation. In a fingerprint classifier, the
proteomic pattern obtained from the panel of markers is
what determines whether or not the individual has a given
disease independent of the discriminating ability of indi-
vidual features within the panel. For example, Zhang and
coworkers used a panel of seven features in a decision tree
classifier to diagnose patients with diffuse large B-cell lym-
phomas (DLBCL) [37], and none of these features showed
significant differences between individuals with and with-
out DLBCL. The MCA procedure [5-10] is an example of a
pure fingerprint-based classifier. In this investigation, the
decision tree classifier was also cast as a fingerprint-based
method since no metric was used to determine which fea-
ture or cut point would be used at a particular decision
node. Even if a metric such at the Gini Index or informa-
tion gain were used, the final decision tree would still
have some fingerprint qualities in that the feature selected
for a given decision node is highly dependent upon which
feature was selected for the preceding decision node. The
more concerted the action of the features becomes, the
more the classifier becomes fingerprint-based.
The final point is that the results presented here can be
considered a chance fitting of the data [1,2], but the Addi-
tional files 1 and 2 show that there is no luck involved. For
datasets with 300 features and 60 Cases and 60 Controls,
the DT classifier was able to find several different classifi-
ers with an average sensitivity and specificity of above
85% for each dataset. At least 200 unique 7-feature MCA
classifiers produced an average sensitivity and specificity
above 90% for each of the five datasets with 90 Cases and
90 Controls. The good classification results are simply due
to the mathematical flexibility of the classifier.
Conclusion
A previous publication has shown that a very accurate fin-
gerprint-based classifier constructed from a finite number
of samples is not necessarily generalizable to the underly-
ing population [14]. This report extends these results to
show that the high accuracy of a fingerprint-based classi-
fier does not necessarily imply any underlying biological
information since accurate results are obtained for a deci-
sion tree and a medoid based classifier using random
datasets with no biological information. A classifier that
correctly fits the data is a necessary condition to reveal
biological relationships, but it is not sufficient.
It has been argued that the measured change in classifica-
tion accuracy for a dataset and the same dataset with the
class labels (histologies) permuted may be a way to meas-
ure the significance of the original classification [36].
Though this will be examined in detail in a later publica-
tion, preliminary results suggest that the drop in classifica-
tion accuracy for the permuted dataset may be exaggerated
if a filtering method is used to identify putative biomark-
ers prior to constructing the final classifier and the origi-
nal dataset contained a putative biomarker. Therefore,
comparing the classification accuracy for a given dataset
against the accuracy of a comparably sized dataset con-
taining random features (i.e. no biological information)
may be a better test.
All 30 random datasets are available online [31] so that
other classification algorithms can be examined. Included
with the datasets is information that more thoroughly
describe the DT and MCA results. In addition, a more
extensive description of the DT and MCA algorithms used
here as well as the actual programs is available [38].
Methods
Since all 30 datasets have 300 peak intensities, the first
step is to set a maximum intensity for each peak. The max-
imum intensity for each peak is set to a random number
between 0.0 and 200.0. For example, Peak 64 is allowed
to have a maximum intensity of only 1.055, while Peak
131 has a maximum intensity of 197.9. A random
number in the range (0.0,1.0) is multiplited by the maxi-
Table 3: Two medoid classification results for the same dataset
Training Set Testing Set
Cases Controls Cases Controls
Result Medoid Corr Incorr Medoid Corr Incorr Corr Incorr Corr Incorr
1 3 5 4 1 3 4 5 11 911 91
2 3 6 3 1 3 6 3 11 911 91
These results are for the same dataset as in Table 2 after a single mixing of the order of Cases and Controls after a hypothetical division of the 
samples into a training set and a testing set. The first classifier uses features 79, 114, 135, 137, 140, 224 and 300, and the second uses features 62, 
65, 141, 146, 156, 211, and 229.BMC Bioinformatics 2008, 9:545 http://www.biomedcentral.com/1471-2105/9/545
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mum allowed intensity to obtain the intensity for a fea-
ture in a given sample. A different seed to the random
number generator is used for each dataset so that the first
sample, for example, has a different intensity for each
peak in each dataset. Since the average maximum inten-
sity is approximately 100.0, the average intensity across all
peaks for a sample is approximately 50.0. To ensure that
no sample varied significantly from this average, each
samples spectrum is scaled so that the sum of all peak
intensities is exactly 15000.0.
Each dataset is constructed to contain the same number of
Cases and Controls (30, 42, 60, 90, 150, and 300 Cases
and Controls). For each number of Cases and Controls, a
total of five random datasets are constructed, producing
30 unique datasets. For each spectrum in each dataset,
peak 64 should have one of the lowest intensities, but it is
possible to have a lower intensity in another peak, even
peak 131, since the intensity is set to a random value
between zero and the maximum allowed.
As described previously [14], the DT and MCA algorithms
use a modified Evolutionary Programming (mEP) algo-
rithm [32] to search for efficient classifiers. The DT algo-
rithm is based on a symmetric seven-node decision tree
(Figure 1). A classifier is represented by an array contain-
ing the peak numbers for the decision nodes 1 through 7,
and an associated array of seven cut points used to deter-
mine which samples are assigned to each of the two
daughter nodes. The mEP procedure ensures that each
decision tree is unique in that the array of seven peak
numbers is different for each tree and that no peak is used
more than once. This means that two decision trees can
use the same set of peaks, but their ordering must be dif-
ferent. For each array of peak numbers, the algorithm
searches through a subset of putative cut points patterns
and keeps the set of cut points that yield the highest qual-
ity. Therefore, the best decision tree obtained at the end of
the run may not be optimum in that a change in one of
more of the cut points may yield better results. In addi-
tion, a very good decision tree may not be found because
either the mEP search did not explore this tree, or a set of
sub-optimum cut points were located yielding a poorer
quality.
Each time a decision tree is constructed, it is examined for
possible pruning. Each decision node is examined before
dividing the samples among the daughter nodes and if the
number of Cases or Controls is less than a given fraction,
F, of the total it is converted to a terminal node. Therefore,
if Node 7 in Figure 1 has a small enough number of Cases
or Controls, it becomes a terminal node. Daughter nodes
14 and 15 are removed and this decision tree only uses six
features. If this decision tree is used to construct a new
tree, the mEP procedure only allows for Nodes 1 through
6 to be changed so that this offspring only contains six
peaks. This DT algorithm is run four times with different
seeds to the random number generator for each dataset.
Two of the runs set F to 1.0%. The other two runs set F to
4.0% so that a decision node is converted to a terminal
node if the number of Cases or Controls is at most 1, 1, 2,
3, 6 or 12 for the datasets with 30, 42, 60, 90, 150, or 300
Cases and Controls, respectively. The terminal nodes of
each decision tree are examined and either labeled as a
Case Node, a Control Node, or an Undetermined Node.
The samples in each node are then used to construct a 2 ×
2 contingency table. For example, if a terminal node con-
tains seven Cases and one Control, it is a Case Node and
the number of true positives (NTP) is increased by seven
and the number of false positives (NFP) is increased by
one. If a terminal node contains two Cases and six Con-
trols, it is denoted a Control Node and the number of false
negatives (NFN) is increased by two and the number of
true negatives (NTN) is increased by six. If the terminal
node contains the same number of Cases and Controls, it
is denoted an Undetermined Node and the classification
of all samples in this node are one-half right and one-half
wrong. Therefore, if this node contains three Cases and
three Controls, NTP, NFP, NFN and NTN are all increased
by 1.5. The quality of this decision tree is the sum of the
sensitivity, NTP/(NTP+NFP), and the specificity, NTN/
(NTN+NFN).
The mEP procedure uses a population size of 200 and
runs for 400 generations if the dataset contains at most 90
Cases and 90 Controls, and a population size of 400 run
for 800 generations if the dataset contains 150 or 300
Cases and Controls. Each time an offspring is created, any
new features placed into the decision tree have 10 random
cut points examined while keeping all other cut points
fixed. All decision nodes then have their cut points set to
five new random values and all combinations of cut
points are examined to find the best combination of cut
points for this set of features. This search is definitely not
exhaustive, so the results should be taken as a lower
bound to the accuracy that can be obtained from a dataset
with no biological information.
The MCA algorithm is similar to the classification algo-
rithm used in studies from the laboratories of Petricoin
and Liotta [5-10] with some exceptions. Each run is
assigned a fixed number of peaks, N, and the mEP proce-
dure ensures that all sets of N peaks stored in the program
are unique. The intensities of these peaks are linearly
scaled to vary between 0.0 and 1.0 and a sample repre-
sents a new cell, or fingerprint pattern, if its Euclidean dis-
tance to any other examined sample is more than the trust
radius of 0.1(N)1/2. The sample's category determines the
category of this cell [5-10]. If the first sample is a Case,
then it defines a Case Cell, or Case Fingerprint Pattern,BMC Bioinformatics 2008, 9:545 http://www.biomedcentral.com/1471-2105/9/545
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and NTP is increased by one. If another Case sample lies
within its trust radius, NTP is increased by one, while if a
Control sample is within this trust radius, NFP is
increased by one. Similarly if a Control sample has a suf-
ficiently unique fingerprint it becomes the medoid of a
Control Cell and NTN is increased by one. If a Case or
Control sample has a fingerprint pattern that is within its
trust radius, NFN or NTN is increased by one, respectively.
To ensure that this fingerprint pattern has complete cover-
age and can be divided into an effective training and test-
ing set, the number of Case Cells or Control Cells cannot
be more than 2/3 of the number of Cases or Controls. If
this is true for a given panel of markers the quality is again
the sum of the sensitivity and specificity, while if too
many of either category of cell is produced the quality is
set to zero. Three pairs of MCA runs are performed for
each dataset, with the number of peaks used in the classi-
fier (N) set to five, six or seven. For each value of N, the
program is run by first examining all Cases and then all
Controls, and by examining all Controls and then all
Cases. The mEP procedure uses a population size of 400
and runs for 800 generations for datasets with 30, 42, 60
and 90 Cases and Controls. For the datasets with 150 and
300 Cases and Controls the population size is increased to
1000 and the search is run for 2000 generations. This
larger search is also used to produce the results in Tables
2 and 3.
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